New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Novo Nordisk A/S

NVO

Healthcare Drug Manufacturers General

Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.

Revenue
+3.87%
EPS
−17.1%
Free cash flow
−14.8%
Total debt
+30.7%

Quarter to September 2026, against a year earlier

38.57 0.32 −0.82%
Market cap
$128.6B
P/E
9.8×
Fwd P/E FY26e
—
Dividend yield
4.62%
F-score
5/9
ROIC
29.6%
Net debt / EBITDA
0.7×
Payout ratio
0.5×

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $20.23 was left as profit. Gross margin has fallen two quarters running, from 86.0% to 77.0%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue12.2100.0%
Cost of revenue−2.8−23.0%
Gross profit9.477.0%
Research & development−3.1−25.1%
Selling, general & admin−2.5−20.5%
Other operating costs−0.3−2.3%
Operating income3.529.1%
Other income, net−0.2−2.0%
Income tax−0.7−5.9%
Other items−0.1−0.9%
Net income2.520.2%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$12.3B$15.2B$12.2B$12.2B
Operating income$5.1B$9.3B$4.2B$3.5B
Net income$3.7B$7.6B$3.2B$2.5B
Net margin (right axis)29.8%50.2%26.3%20.2%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
12,196.03 12,212.73 15,162.48 12,343.02

+8 more quarters

Revenue Growth
3.87% 4.47% 37.61% 0.67%
Gross Profit
9,387.53 9,551.97 13,033.04 10,018.94
Operating Income
3,543.69 4,210.69 9,336.18 5,057.82
EBT
3,300.84 4,181.75 9,736.14 5,400.70
Income after Tax
2,577.96 3,265.89 7,604.03 4,247.77
Net Income Common
2,577.96 3,265.89 7,604.03 4,247.77
EPS (Diluted)
0.58 0.74 1.71 0.94
Shares (Diluted, Weighted)
4,416.58 4,435.80 4,449.40 4,447.70
Gross Margin
76.97% 78.21% 85.96% 81.17%
EBIT Margin
29.06% 34.48% 61.57% 40.98%
Net Profit Margin
21.14% 26.74% 50.15% 34.41%
EBITDA
5,734.84 5,810.46 9,889.92 5,814.52
EBIT
3,543.69 4,210.69 9,336.18 5,057.82

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026